Pro-Pharmaceuticals, Mt. Sinai School of Medicine to collaborate in liver fibrosis research

By Lisa Kerner

Erie, Pa., May 24 - Pro-Pharmaceuticals, Inc. said it has entered into a research collaboration with Mount Sinai School of Medicine to evaluate the anti-fibrotic effects of some of the company's novel, carbohydrate compounds.

A program has been established to develop and test potential anti-fibrotic compounds in cultured cells, in animal models of hepatic fibrosis and in clinical trials of patients with chronic liver disease.

All chronic liver diseases can cause fibrosis, or scarring, which may lead to liver failure and transplantation. There are no approved anti-fibrotic treatments for patients with liver disease, according to a company news release.

"Collaborating with Mount Sinai represents an exciting opportunity to partner with a premier liver research program to develop a novel method for treating liver disease," president and chief executive officer David Platt said in the release.

About 25 million Americans, or one in 10, are or have been afflicted with liver and biliary diseases, according to the American Liver Foundation.

Located in Newton, Mass., Pro-Pharmaceuticals discovers, develops and commercializes nanotechnology carbohydrate therapeutics for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.